The fibroblast growth factor receptor inhibitor PD173074 blocks small cell lung cancer growth in vitro and in vivo.
暂无分享,去创建一个
Eric O. Aboagye | Michael J. Seckl | Gordon W. Stamp | B. Spencer‐Dene | G. Stamp | R. Poulsom | O. Pardo | M. Seckl | R. Jeffery | N. Lemoine | E. Aboagye | E. Nye | Richard Poulsom | Olivier E. Pardo | John Latigo | Rosemary E. Jeffery | Emma Nye | Bradley Spencer-Dene | Nick R. Lemoine | J. Latigo
[1] B. Ng,et al. Fibroblast Growth Factor 2-Mediated Translational Control of IAPs Blocks Mitochondrial Release of Smac/DIABLO and Apoptosis in Small Cell Lung Cancer Cells , 2003, Molecular and Cellular Biology.
[2] N. Sebire,et al. FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCepsilon, B-Raf and S6K2. , 2006, The EMBO journal.
[3] P. Cohen,et al. The specificities of protein kinase inhibitors: an update. , 2003, The Biochemical journal.
[4] J. Au,et al. Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[5] Neil J. Sebire,et al. FGF‐2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B‐Raf and S6K2 , 2006 .
[6] D. Blakey,et al. Sensitization of Tumor-Associated Endothelial Cell Apoptosis by the Novel Vascular-Targeting Agent ZD6126 in Combination with Cisplatin , 2004, Clinical Cancer Research.
[7] E. Rozengurt. Autocrine loops, signal transduction, and cell cycle abnormalities in the molecular biology of lung cancer. , 1999, Current opinion in oncology.
[8] T. Dougherty,et al. Anti-Angiogenic Activity of Selected Receptor Tyrosine Kinase Inhibitors, PD166285 and PD173074: Implications for Combination Treatment with Photodynamic Therapy , 2004, Investigational New Drugs.
[9] Co-targeting IGF-1R and c-kit: synergistic inhibition of proliferation and induction of apoptosis in H 209 small cell lung cancer cells , 2004, British Journal of Cancer.
[10] Tim Eisen,et al. Kinase Inhibition with BAY 43–9006 in Renal Cell Carcinoma , 2004, Clinical Cancer Research.
[11] E. Turley,et al. Cell motility, invasion, and malignancy induced by overexpression of K-FGF or bFGF. , 1993, Experimental cell research.
[12] R. Friesel,et al. Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[13] A. Baird. Potential mechanisms regulating the extracellular activities of basic fibroblast growth factor (FGF‐2) , 1994, Molecular reproduction and development.
[14] J. Blusztajn,et al. Acetylcholine is synthesized by and acts as an autocrine growth factor for small cell lung carcinoma. , 2003, Cancer research.
[15] Paul Workman,et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography. , 2006, Cancer research.
[16] S. Hubbard,et al. Crystal structure of an angiogenesis inhibitor bound to the FGF receptor tyrosine kinase domain , 1998, The EMBO journal.
[17] Jiehua Zhou,et al. Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] Qimin He,et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. , 2003, Cancer research.
[19] I. Gout,et al. Novel cross talk between MEK and S6K2 in FGF-2 induced proliferation of SCLC cells , 2001, Oncogene.
[20] P. Woll,et al. Production and upregulation of granulocyte chemotactic protein-2/CXCL6 by IL-1β and hypoxia in small cell lung cancer , 2006, British Journal of Cancer.
[21] G. Bepler,et al. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.